The role of α2-adrenoceptor antagonism in the anti-cataleptic properties of the atypical neuroleptic agent, clozapine, in the rat

British Journal of Pharmacology

Volumn 124, Issue 7, 1998, Pages 1550-1556

  Kalkman, Hans O ^a   Neumann, Vroni ^a   Hoyer, Daniel ^a   Tricklebank, Mark D ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

2 adrenoceptor antagonists; Catalepsy; Clozapine; Loxapine; Neuroleptic drugs; RX 821002; Yohimbine

Indexed keywords

1,3,4,5',6,6',7,12B OCTAHYDRO 1',3' DIMETHYL 2H SPIRO[BENZO[B]FURO[2,3 A]QUINOLIZINE 2,4' PYRIMIDINE] 2' ONE; 2 (2 METHOXY 1,4 BENZODIOXAN 2 YL) 2 IMIDAZOLINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ALPHA 2 ADRENERGIC RECEPTOR; CLOZAPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; HALOPERIDOL; LOXAPINE; NEUROLEPTIC AGENT; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; YOHIMBINE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BENZAZEPINE DERIVATIVE; DRUG DERIVATIVE; MDL 100,151; PYRIDINE DERIVATIVE; SEROTONIN ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALEPSY; CONTROLLED STUDY; DOSE RESPONSE; EXTRAPYRAMIDAL SYMPTOM; LIGAND BINDING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; RECEPTOR BLOCKING; SUBCUTANEOUS DRUG ADMINISTRATION; ANIMAL; DRUG ANTAGONISM; HUMAN; WISTAR RAT;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZAZEPINES; CATALEPSY; CLOZAPINE; HUMANS; LOXAPINE; MALE; PYRIDINES; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, ALPHA-2; SEROTONIN ANTAGONISTS;

EID: 0031595232     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701975     Document Type: Article

References (44)

1. ANDERSON, R.J. (1985). Modification of resperine induced rigidity by dopaminergic and alpha-adrenergic drugs. Acta Neurol. Scand., 72, 584-589.
2. BALDESSARINI, R.J. & FRANKENBURG, F.R. (1991). Clozapine, a novel antipsychotic agent. N. Engl. J. Med., 324, 746-754.
3. BALDESSARINI, R.J., HUSTON-LYONS, D., CAMPBELL, A., MARSH, E. & COHEN, B.M. (1992). Do central antiadrenergic actions contribute to the atypical properties of clozapine? Br. J. Psychiat., 160, 12-16.
4. 1A receptors are not involved in clozapine's lack of cataleptogenic potential. Neuropharmacol., 11, 1645-1646.
5. BREIER, A., BUCHANAN, R.W., WALTRIP, R.W., LISTWAK, S., HOLMES, C. & GOLDSTEIN, D.S. (1994). The effect of clozapine on plasma norepinephrine: relationship to clinical efficacy. Neuropsychopharmacol., 10, 1-7.
6. 1D binding sites in various species: similar pharmacological profile in calf, guinea-pig, dog, monkey and human brain membranes. Naunyn Schmiedeberg's Arch. Pharmacol., 346, 243-248.
7. BUCHSBAUM, M.S. (1995). Charting the circuits. Nature, 378, 128-129.
8. BYLUND, D.B., EIKENBERG, D.C., HIEBLE, J., LANGER, S.Z., LEFKOWITZ, R.J., MINNEMAN, K.P., MOLINOFF, P.B., RUFFOLO, JR. R.R. & TRENDELENBURG, U. (1994). International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol. Rev., 46, 121-136.
9. CHIODO, L.A. & BUNNEY, B.S. (1983). Typical and atypical neuroleptics: Differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. Neurosci., 3, 1607-1619.
10. DURIF, F., VIDAILHET, M., ASSAL, F., ROCHE, C., BONNET, A.M. & AGID, Y. (1997). Low-dose of clozapine improves dyskinesia in Parkinson's disease. Neurol., 48, 658-662.
11. ELLIOTT, P.J., WALSH, D.M., CLOSE, S.P., HIGGINS, G.A. & HAYES, A.G. (1990). Behavioural effects of serotonin antagonists in the rat and marmoset. Neuropharmacol., 29, 949-956.
12. 1-adrenoceptors, Eur. J. Pharmacol., 73, 221-224.
13. FACTOR, S.A. & FRIEDMAN, J.H. (1997). The emerging role of clozapine in the treatment of movement disorders. Movement Disorders, 12, 483-496.
14. GOMEZ-MANCILLA, B. & BEDARD, P.J. (1993). Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. Clin. Neuropharmacol., 16, 418-427.
15. HOFFMAN, D.C. & DONOVAN, H. (1995). Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacol., 120, 128-133.
16. 3H]ketanserin. Eur. J. Pharmacol., 118, 13-23.
17. HUNZIKER, F., FISCHER, R., KIPFER, P., BUERKI, H.R., EICHENBERGER, E. & WHITE, T.G. (1981). Seven-membered heterocycles. 28. Neuroleptic piperazinyl derivatives of 10H-thieno[3,2-c][1]benzazepines and 4H-thieno[2,3-c][1]benzazepines. Eur. J. Med. Chem., 16, 391-398.
18. JOSSELYN, S.A., MILLER, R. & BENINGER, R.J. (1997). Behavioral effects of clozapine and dopamine receptor subtypes. Neuroscience and Biobehav. Rev., 21, 531-558.
19. KALKMAN, H.O., NEUMANN, V. & TRICKLEBANK, M.D. (1997). Clozapine inhibits catalepsy induced by olanzapine and loxapine, but prolongs catalepsy induced by SCH 23390 in rats. Naunyn-Schmiedeberg's Arch. Pharmacol., 355, 361-364.
20. KALKMAN, H.O., NEUMANN, V., NOZULAK, J. & TRICKLEBANK, M.D. (1998). Cataleptogenic effect of subtype selective 5-HT receptor antagonists in the rat. Eur. J. Pharmacol., 343, 201-207.
21. 2 antagonism and EPS benefits: is there a causal connection? Psychopharmacol., 124, 35-39.
22. 2-adrenoceptors. J. Psychopharmacol., 10 (suppl.), 2-5.
23. 2 receptors. Psychopharmacol., 112, S40-S54.
24. MARKSTEIN, R., GULL, P., RUEDEBERG, C., URWYLER, S., JATON, A.L., MCALLISTER, K., DIXON, K. & HOYER, D. (1996). SDZ PSD 958, a novel D-1 receptor antagonist with potential limbic selectivity. J. Neural Transmission, 103, 261-276.
25. MCMILLAN, B.A., SCOTT, S.M. & DAVANZO, E.A. (1988). Reversal of neuroleptic-induced catalepsy by novel aryl-piperazine anxiolytic drugs. J. Pharm. Pharmacol., 40, 885-887.
26. 1 values. J. Pharmacol. Exp. Ther., 251, 238-246.
27. MOORE, N.A., CALLIGARO, D.O., WONG, D.T., BYMASTER, F. & TYE, N.C. (1993). The pharmacology of olanzapine and other new antipsychotic agents. Curr. Opin. Invest. Drugs, 2, 281-293.
28. 1A receptors. Neuropharmacol., 35, 119-121.
29. 2-adrenoceptor antagonism account for the therapeutic advantage of new antipsychoties? J. Psychopharmacol., 8, 193-195.
30. 2 adrenoceptors in the human brain. J. Pharmacol. Exp. Ther., 264, 967-976.
31. 2-adrenergic receptor subtype mRNAs in human tissue. Molec. Brain Res., 16, 57-63.
32. PRINSSEN, E.P.M., ELLENBROEK, B.A. & COOLS, A.R. (1994). Combined antagonism of adrenoceptors and dopamine and 5-HT receptors underlies the atypical profile of clozapine. Eur. J. Pharmacol., 262, 167-170.
33. ROBERTSON, G.S. & FIBIGER, H.C (1992). Neuroleptics increase C-Fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neurosci., 46, 315-328.
34. 2-adrenoceptor agonist. Mol. Pharmacol., 51, 36-46.
35. 2-adrenergic receptor subtype gene expression in the rat brain. Mol. Brain. Res., 21, 133-149.
36. SCHMUTZ, J. & EICHENBERGER, E. (1982). In Chronicles of drug discovery. ed. Bindra, J.S. & Hednicer, D. pp. 39-59. Chichester: John Wiley & Sons.
37. SCHOTTE, A., JANSSEN, P.F.M., GOMMEREN, W., LUYTEN. W.H.M.L., VAN GOMPEL, P., LESAGE, A.S., DE LOORE, K. & LEYSEN, J.E. (1996). Risperidonc compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacol., 124, 57-73.
38. 4 receptors. Neuropsychopharmacol., 16, 93-110.
39. 2A receptors in antipsychotic and anticataleptic action. J. Psychopharmacol., 11, 15-17.
40. 2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral electrophysiological and neurochemical studies. J. Pharmacol. Exp. Ther., 266, 684-691.
41. 2-autoreceptors: rat vena cava, rat atria, human kidney and guinea-pig urethra. Naunyn-Schmiedeberg's Arch. Pharmacol., 356, 721-737.
42. 2 dopamine and N-methyl-D-aspartate (NMDA) receptor participation in experimental catalepsy in rats. Psychopharmacol., 109, 477-483.
43. WADENBERG, M.L. (1992). Antagonism by 8-OH-DPAT, hut not ritanserin, of catalepsy induced by SCH 23390 in the rat. J. Neural. Transm., 89, 49-59.
44. YOUNG, K.A., RANDALL, P.K. & WILCOX, R.E. (1995). Startle and sensorimotor correlates of ventral thalamic dopamine and GABA in rodents. Neuroreport, 6, 2495-2499.